Your AI-Trained Oncology Knowledge Connection!
Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.
Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.
Dr Somaiah discusses the excitement surrounding novel agents such as CSF1R inhibitors and ULK1/2 inhibitors, and the utility of broad spectrum TKIs such as ripretinib.
Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.
Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.
Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raising awareness about this breast cancer subset to propel further research.
Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to address disparities in these areas, and specific ways that Dana-Farber is working to close these gaps.
Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.
Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.
Drs Ramkumar and Morganstein discuss the challenges they face with integrating and organizing molecular testing results into electronic medical records, how they address non–small cell lung cancer test results with patients, and their hopes for the future of pathology at their institutions.
Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.
Dr Velcheti discusses planned research into whether mobile technology services can improve patient outcomes for underserved and underrepresented patient populations.
Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.
Dr Leal discusses the symptoms commonly associated with Lambert-Eaton Myasthenic Syndrome, the prevalence of this disorder in concurrence with underlying cancers, and how amifampridine can help manage this disease by improving motor and autonomic symptoms.
Dr Elamin discusses results from a phase 2 study of poziotinib efficacy in EGFR exon 20–mutant non–small cell lung cancer and highlights the agent’s sensitivity in relation to insertion location.
Dr Chen details the findings from a study of patients with transformed cutaneous T-cell lymphoma, gives her perspective on findings from the FLASH trial, and discusses the need for more research funding in this disease.
Drs Bekaii-Saab, George, and von Mehren discuss patient-reported outcomes from the INTRIGUE trial, the rationale for a phase 1/2 study investigating DCC-3116 in patients with RAS or RAF–mutated solid tumors, and how vimseltinib may alleviate unmet needs in the tenosynovial giant cell tumors population.
Dr Petrylak discusses current issues with genetic testing and disease management in prostate and bladder cancer, some of the reasons for poor testing rates, and the importance of proper multidisciplinary management during testing and when seeking to mitigate adverse effects.
Dr Katz discusses the implications of a recently published phase 2 study investigating neoadjuvant mFOLFIRINOX with or without hypofractionated radiation therapy results for patients with borderline resectable pancreatic ductal adenocarcinoma.
Dr Gradishar emphasizes the importance of defining metastatic breast cancer subtypes, the implications of molecular testing on treatment decisions, and the need for comprehensive patient-provider communication about therapeutic options and clinical trial opportunities throughout the course of disease.
Michael J. Wagner, MD, talks about the struggle to investigate angiosarcoma, the ways research cooperatives have had recent success in driving the science forward, and the potential for immunotherapy in this disease.
Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.
Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.
Dr. Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.
Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.
Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.
Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.
Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.
Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.
